暗記メーカー

暗記メーカー

​
ログイン

MTLBE- SUHO NOTES

MTLBE- SUHO NOTES
86問 • 2年前
  • Yves Laure Pimentel
    • 通報

    問題一覧

  • 1

    PHILIPPINE MEDICAL TECHNOLOGY ACT OF 1969 JUNE 21, 1969 32 SECTIONS

    RA 5527

  • 2

    RA 5527

    PHILIPPINE MEDICAL TECHNOLOGY ACT OF 1969 JUNE 21, 1969 32 SECTIONS

  • 3

    AMENDMENTS ON RA 5527

    RA 6138 , PD 498, PD 1534

  • 4

    Amends Sections 14 ,21, and 22

    RA 6138 (August 31, 1970)

  • 5

    PD 498 (June 28, 1974)

    Amends Sections 2,3,4,7,8,11,13,16,17,21 and 29

  • 6

    Amends Sections 2,3,4,7,8,11,13,16,17,21 and 29

    PD 498 (June 28, 1974)

  • 7

    PD 1534 (June 11, 1978)

    Amends Sections 3,8 and 13

  • 8

    Amends Sections 3,8 and 13

    PD 1534 (June 11, 1978)

  • 9

    TERM OF OFFICE BOARD OF MT HOLD OFFICE FOR ? AFTER APPOINTMENTS OR UNTIL THEIR SUCCESSORS SHALL HAVE BEEN APPOINTED AND DULY QUALIFIED

    THREE YEARS

  • 10

    BEFORE THE BOARD OR BEFORE ANY PERSON AUTHORIZED TO ADMINISTER PATHS PRIOR TO ENTERING UPON THE PRACTICE OF MT

    OATHTAKING

  • 11

    ISSUANCE OF COR ISSUED TO ANY SUCCESFUL APPLICANT WHO HAS ATTAINED?

    AGE OF 21 YEARS

  • 12

    ADMINISTRATIVE INVESTIGATION CONDUCTED BY ?

    ATLEAST TWO MEMBERS OF THE BOARD WITH ONE LEGAL OFFICER

  • 13

    UNANIMOUS VOTE OF ALL THREE MEMBERS OF THE BOARD

    REVOCATION

  • 14

    MAJORITY VOTE; NOT TO EXCEED 2 YEARS

    SUSPENSION

  • 15

    SUSPENSION MAJORITY VOTE; NOT TO

    EXCEED 2 YEARS

  • 16

    CLINICAL LABORATORY ACT JUNE 18, 1966

    RA 4688

  • 17

    RA 4688

    CLINICAL LABORATORY ACT JUNE 18, 1966

  • 18

    REVISED RULES AND REGULATIONS GOVERNING THE LICENSURE OF CLINICAL LABORATORIES IN THE PHILIPPINES AUGUST 22, 2007

    AO No 2007-0027

  • 19

    AO No 2007-0027 DATE

    AUGUST 22, 2007

  • 20

    PRIMARY CATEGORY LABORATORY

    ROUTINE HEMATOLOGY QUALITATIVE PLATELET DETERMINATION ROUTINE URINALYSIS ROUTINE FECALYSIS BLOOD TYPING - FOR HOSPITAL BASED

  • 21

    ROUTINE HEMATOLOGY QUALITATIVE PLATELET DETERMINATION ROUTINE URINALYSIS ROUTINE FECALYSIS BLOOD TYPING - FOR HOSPITAL BASED

    PRIMARY CATEGORY LABORATORY

  • 22

    SECONDARY CATEGORY LABORATORY

    SERVICES OF PRIMARY CATEGORY LABORATORY ROUTINE CC QUANTITATIVE PLATELET DETERMINATION CROSS-MATCHING- FOR HOSPITAL BASED GRAM STAINING- FOR HOSPITAL BASED KOH- FOR HOSPITAL BASED

  • 23

    SERVICES OF PRIMARY CATEGORY LABORATORY ROUTINE CC QUANTITATIVE PLATELET DETERMINATION CROSS-MATCHING- FOR HOSPITAL BASED GRAM STAINING- FOR HOSPITAL BASED KOH- FOR HOSPITAL BASED

    SECONDARY CATEGORY LABORATORY

  • 24

    VALIDITY OF LTO CLINICAL LABORATORY

    1 YEAR

  • 25

    NON HOSPITAL BASED CLINICAL LABORATORIES SHALL FILES APPILICATIONS FOR RENEWAL OF LTO ? OF THE CURRENT YEAR

    BEGINNING ON THE FIRST DAY OF OCTOBER UNTIL THE LAST DAY OF NOVEMBER

  • 26

    BLOOD BANKING LAW OF 1956 JUNE 16, 1956

    RA 1517

  • 27

    RA 1517

    BLOOD BANKING LAW OF 1956 JUNE 16, 1956

  • 28

    NATIONAL BLOOD SERVICES ACT OF 1994 MAY 5 1994

    RA 7719

  • 29

    RA 7719

    NATIONAL BLOOD SERVICES ACT OF 1994 MAY 5 1994

  • 30

    GUIDELINES ON THE IMPLEMENTATION OF RAPID HIV DIAGNOSTIC ALGORITHM JANUARY 10, 2019

    DOH A.O. NO. 2019-0001

  • 31

    DOH A.O. NO. 2019-0001 DATE

    JANUARY 10, 2019

  • 32

    All results of HIV/AIDS testing shall be confidential and shall be released only to the folowing persons The person who submitted himself/herself to such a test either parent of a minor child who has been tested a legal guardian in the case of insane persons or orphans a person authorized to recelve such results in conjunction with the AIDSWATCH program a justice of the Court of Appeals or the Supreme Court

    HIV RESULT : RA 8504

  • 33

    PHILIPPINE HIV AND AIDS POLICY ACT DECEMBER 20, 2018

    RA 11166

  • 34

    RA 11166

    PHILIPPINE HIV AND AIDS POLICY ACT DECEMBER 20, 2018

  • 35

    Results of any test related to HIV shall be disclosed by the trained service provider who conducts pre-test and post-test counseling to: *Individual who submitted to the test. *If the patient is below fifteen (15) years old, an orphan, or is mentally incapacitated, the result may de disclose to either of the patient's parents, legal guardian, or a duly assigned licensed social worker or health worker, whichever is applicable *A person below fifteen(15) years of age and not suffering from any mental incapacity, has given voluntary and informed consent to the procedure, the result of the test shall be disclose to child, provided that the child should be given age-appropriate counseling and access to necessary health care and sufficient support services. *Person authorized to receive such results in conjunction with the DOH *Monitoring Body.

    HIV RESULT: RA 11166

  • 36

    NEWBORN SCREENING ACT OF 2004 APRIL 7, 2004 DISORDERS SCREENED: - CONGENITAL HYPOTHYROIDISM - CONGENITAL ADRENAL HYPERPLASIA - GALACTOSEMIA - PHENYLKETONURIA - G6PD DEFICIENCY

    RA 9288

  • 37

    WHAT IS RA 9288 , DATE AND DISORDERS SCREENED

    NEWBORN SCREENING ACT OF 2004 APRIL 7, 2004 DISORDERS SCREENED: - CONGENITAL HYPOTHYROIDISM - CONGENITAL ADRENAL HYPERPLASIA - GALACTOSEMIA - PHENYLKETONURIA - G6PD DEFICIENCY

  • 38

    INCLUSION OF MSUP IN NEWBOR SCREENING. MSUD APPEARS TO BE THE MOST COMMON INBORN ERROR OF METABOLISM IN THE PHILIPPINES

    DOH MEMO 2012-0154

  • 39

    EXPANDED NEWBORN SCREENING INCREASE THE SCREENING PANEL OF DISORDERS FORM?

    6 TO 28

  • 40

    INCREASE THE SCREENING PANEL OF DISORDERS FORM 6 TO 28

    EXPANDED NEWBORN SCREENING

  • 41

    Dangerous DRUG ACT OF 1972

    RA 6425

  • 42

    RA 6425

    Dangerous DRUG ACT OF 1972

  • 43

    COMPRHENSIVE DANGEROUS DRUG ACT OF 2002

    RA 9165

  • 44

    RA 9165

    COMPRHENSIVE DANGEROUS DRUG ACT OF 2002

  • 45

    methylenedioxymethamphetamine

    ECSTASY

  • 46

    ECSTASY

    methylenedioxymethamphetamine

  • 47

    CANNABIS

    MARIJUANA OR INDIAN HEMP

  • 48

    MARIJUANA OR INDIAN HEMP

    CANNABIS

  • 49

    METHAMPETHAMINE HYDROCHLORIDE

    SHABU, ICE, OR METH

  • 50

    SHABU, ICE, OR METH

    METHAMPETHAMINE HYDROCHLORIDE

  • 51

    INDIVIDUAL FROM WHOM A SPECIMEN IS COLLECTED

    DONOR/CLIENT

  • 52

    DRUG TEST IS VALID FOR?

    1 YEAR

  • 53

    ACRREDITATION OF DRUG TESTING LABORATORY

    DOH

  • 54

    HEAD OF DRUG SCREENING LABORATORY IN CASES WHERE THE SCREENING DRUG TESTING LABORATORY IS A DIVISION, SECTION, OR UNIT OF CLINICAL LABORATORY, IT SHALL BE HEADED BY A LICENSED PHYSICIAN, CHEMIST, MEDICAL TECHNOLOGIST, PHARMACIST OR CHEMICAL ENGINEER.

    PATHOLOGIST

  • 55

    HEAD OF DRUG SCREENING LABORATORY IN CASES WHERE THE SCREENING DRUG TESTING LABORATORY IS A DIVISION, SECTION, OR UNIT OF CLINICAL LABORATORY, IT SHALL BE HEADED BY A LICENSED ?

    PHYSICIAN, CHEMIST, MEDICAL TECHNOLOGIST, PHARMACIST OR CHEMICAL ENGINEER.

  • 56

    HEAD OF DRUG CONFIRMATORY LABORATORY PATHOLOGIST WITH AT LEAST HOW MANY YEARS ACTIVE LABORATORY EXPERIENCE IN ANALYTICAL TOXICOLOGY

    2 YEARS

  • 57

    STUDENTS OF SECONDARY AND TERTIARY SCHOOLS OFFICERS AND EMPLOYEES OF PUBLIC AND PRIVATE OFFICES WHETHER DOMESTIC OR OVERSEAS

    RANDOM DRUG TEST

  • 58

    ACCREDITATION OF DRUG TESTING LAB VALID FOR A PERIOD OF:

    1 YEAR FOR SCREENING LABORATORY 2 YEARS FOR CONFIRMATORY LABORATORY

  • 59

    WHAT AO RULES AND REGULATIONS GOVERNING THE ACCREDITATION OF LABORATORIES FOR DRINKING WATER ANALYSIS 1. PHYSICAL ANALYSIS 2. CHEMICAL ANALYSIS 3. RADIOLOGICAL ANALYSIS 4. BACTERIOLOGIC ANALYSIS

    DOH A.O. No. 2006-0024

  • 60

    RULES AND REGULATIONS GOVERNING THE ACCREDITATION OF LABORATORIES FOR DRINKING WATER ANALYSIS (4)

    1. PHYSICAL ANALYSIS 2. CHEMICAL ANALYSIS 3. RADIOLOGICAL ANALYSIS 4. BACTERIOLOGIC ANALYSIS

  • 61

    ACCREDITATION OF LAB FOR DRINKING WATER ANALYSIS

    2 YEARS AND EXPIRES ON THE LAST DAY OF DECEMBER

  • 62

    CREATION OF PRC JUNE 22, 1973

    PD 223

  • 63

    PD 223

    CREATION OF PRC JUNE 22, 1973

  • 64

    PRC MODERNIZATION ACT OF 2000 DECEMBER 5, 2000 THREE MAN COMISSION - TEOFILO PILANDO -YOLANDA REYES - JOSE CUTEO, JR.

    RA 8981

  • 65

    RA 8981

    PRC MODERNIZATION ACT OF 2000 DECEMBER 5, 2000

  • 66

    THREE MAN COMISSION

    - TEOFILO PILANDO -YOLANDA REYES - JOSE CUTEO, JR.

  • 67

    CONTINUING PROFESSIONAL DEVELOPMENTAL ACT OF 2016

    RA 10912

  • 68

    RA 10912

    CONTINUING PROFESSIONAL DEVELOPMENTAL ACT OF 2016

  • 69

    45 CREDITS UNITS REQUIRED FOR MT EVERY 3 YEARS

    PRC Resolution No. 2016-990

  • 70

    PRC Resolution No. 2016-990 ? CREDITS UNITS REQUIRED FOR MT EVERY 3 YEARS

    45

  • 71

    PRC Resolution No. 2016-990 45 CREDITS UNITS REQUIRED FOR MT EVERY ?

    3 YEARS

  • 72

    CPD shall reduced the required CPD credit units to a minimum, which shall not be more than 15 units Professional working overseas shall NOT be covered by CPD requirement Newly Licensed professionals shall NOT be covered by the CPD requirement for the first renewal cycle.

    PRC Resolution No. 2019-1146

  • 73

    CPD shall reduced the required CPD credit units to a minimum, which shall not be more than ? units

    15

  • 74

    Contains your specific promises to: 1. Undertake to comply with the required number of CPD credit units during the validity of your PRC ID 2. Submit proof of compliance with the required number of CPD units during the next renewal of PRC ID.

    AFFIDAVIT OF UNDERTAKING

  • 75

    FAILURE TO GIVE REASONABLE CARE BY THE HEALTH-CARE PROVIDER

    NEGLIGENCE

  • 76

    MISCONDUCT OR LACK SKILL BY A HEALTH-CARE PROFESSIONAL THAT RESULTS IN INJURY TO THE PATIENT

    MEDICAL MALPRACTICE

  • 77

    Respecting the decisions made by those capable of making decisions. also includes respecting the _ of people whose ability to make decisions is limited.

    AUTONOMY

  • 78

    Doing good or providing benefit

    BENEFICIENCE

  • 79

    Avoid doing harm, or minimize harm as much as possible if it is unavoidable

    NON-MALEFICENCE

  • 80

    Ensuring fairness and equity in the distribution of risks and benefits. This includes the idea of treating equals equally and recognizing relevant inequalities

    JUSTICE

  • 81

    4 MANAGEMENT

    PLANNING ORGANIZING DIRECTING CONTROLLING

  • 82

    Identifying goals, evaluate current situation, establish time frame, set objectives, forecast resource need, implement plan, obtain feedback.

    PLANNING

  • 83

    Formal hierarchy, informal relationships

    ORGANIZING

  • 84

    Leadership, time allocation

    DIRECTING

  • 85

    Instructions, follow-up, modifications

    CONTROLLING

  • 86

    PROVIDES RECOMMENDATION FOR THE NUMBER OF STAFF (PHLEBOTOMISTS, CLERKS, TECHNICAL PERSONNEL, AND SO ON) NEEDED TO HANDLE AN UNPREDICTABLE WORKLOAD.

    QUEUING THEORY

    • other names parasitology

    other names parasitology

    Yves Laure Pimentel · 70問 · 2年前

    other names parasitology

    other names parasitology

    70問 • 2年前
    Yves Laure Pimentel

    PARASITOLOGY

    PARASITOLOGY

    Yves Laure Pimentel · 111問 · 2年前

    PARASITOLOGY

    PARASITOLOGY

    111問 • 2年前
    Yves Laure Pimentel

    HTMLBE

    HTMLBE

    Yves Laure Pimentel · 64問 · 2年前

    HTMLBE

    HTMLBE

    64問 • 2年前
    Yves Laure Pimentel

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    Yves Laure Pimentel · 61問 · 2年前

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    61問 • 2年前
    Yves Laure Pimentel

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    Yves Laure Pimentel · 69問 · 2年前

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    69問 • 2年前
    Yves Laure Pimentel

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    Yves Laure Pimentel · 100問 · 2年前

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    100問 • 2年前
    Yves Laure Pimentel

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    Yves Laure Pimentel · 41問 · 2年前

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    41問 • 2年前
    Yves Laure Pimentel

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    Yves Laure Pimentel · 87問 · 2年前

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    87問 • 2年前
    Yves Laure Pimentel

    CSF 1

    CSF 1

    Yves Laure Pimentel · 100問 · 2年前

    CSF 1

    CSF 1

    100問 • 2年前
    Yves Laure Pimentel

    CSF 2

    CSF 2

    Yves Laure Pimentel · 82問 · 2年前

    CSF 2

    CSF 2

    82問 • 2年前
    Yves Laure Pimentel

    SEMEN 1

    SEMEN 1

    Yves Laure Pimentel · 100問 · 2年前

    SEMEN 1

    SEMEN 1

    100問 • 2年前
    Yves Laure Pimentel

    SEMEN 2

    SEMEN 2

    Yves Laure Pimentel · 7問 · 2年前

    SEMEN 2

    SEMEN 2

    7問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    Yves Laure Pimentel · 100問 · 2年前

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    100問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    Yves Laure Pimentel · 6問 · 2年前

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    6問 • 2年前
    Yves Laure Pimentel

    SEROUS FLUID

    SEROUS FLUID

    Yves Laure Pimentel · 25問 · 2年前

    SEROUS FLUID

    SEROUS FLUID

    25問 • 2年前
    Yves Laure Pimentel

    PLEURAL FLUID

    PLEURAL FLUID

    Yves Laure Pimentel · 44問 · 2年前

    PLEURAL FLUID

    PLEURAL FLUID

    44問 • 2年前
    Yves Laure Pimentel

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    Yves Laure Pimentel · 18問 · 2年前

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    18問 • 2年前
    Yves Laure Pimentel

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    Yves Laure Pimentel · 30問 · 2年前

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    30問 • 2年前
    Yves Laure Pimentel

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    Yves Laure Pimentel · 92問 · 2年前

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    92問 • 2年前
    Yves Laure Pimentel

    FECALYSIS

    FECALYSIS

    Yves Laure Pimentel · 80問 · 2年前

    FECALYSIS

    FECALYSIS

    80問 • 2年前
    Yves Laure Pimentel

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    Yves Laure Pimentel · 89問 · 2年前

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    89問 • 2年前
    Yves Laure Pimentel

    MTLBE..

    MTLBE..

    Yves Laure Pimentel · 35問 · 2年前

    MTLBE..

    MTLBE..

    35問 • 2年前
    Yves Laure Pimentel

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    Yves Laure Pimentel · 19問 · 1年前

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    19問 • 1年前
    Yves Laure Pimentel

    CC-OSMOMETRY

    CC-OSMOMETRY

    Yves Laure Pimentel · 14問 · 1年前

    CC-OSMOMETRY

    CC-OSMOMETRY

    14問 • 1年前
    Yves Laure Pimentel

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    Yves Laure Pimentel · 43問 · 1年前

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    43問 • 1年前
    Yves Laure Pimentel

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    Yves Laure Pimentel · 49問 · 2年前

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    49問 • 2年前
    Yves Laure Pimentel

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    Yves Laure Pimentel · 97問 · 2年前

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    97問 • 2年前
    Yves Laure Pimentel

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    Yves Laure Pimentel · 57問 · 2年前

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    57問 • 2年前
    Yves Laure Pimentel

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    Yves Laure Pimentel · 63問 · 2年前

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    63問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 37問 · 2年前

    PROTEINS

    PROTEINS

    37問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    Yves Laure Pimentel · 91問 · 2年前

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    91問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    Yves Laure Pimentel · 98問 · 2年前

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    98問 • 2年前
    Yves Laure Pimentel

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    Yves Laure Pimentel · 61問 · 2年前

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    61問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 1

    Liver Function Test 1

    Yves Laure Pimentel · 100問 · 2年前

    Liver Function Test 1

    Liver Function Test 1

    100問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 2

    Liver Function Test 2

    Yves Laure Pimentel · 96問 · 2年前

    Liver Function Test 2

    Liver Function Test 2

    96問 • 2年前
    Yves Laure Pimentel

    TUMOR MARKERS

    TUMOR MARKERS

    Yves Laure Pimentel · 33問 · 2年前

    TUMOR MARKERS

    TUMOR MARKERS

    33問 • 2年前
    Yves Laure Pimentel

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    Yves Laure Pimentel · 41問 · 2年前

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    41問 • 2年前
    Yves Laure Pimentel

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    Yves Laure Pimentel · 17問 · 2年前

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    17問 • 2年前
    Yves Laure Pimentel

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    Yves Laure Pimentel · 14問 · 2年前

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    14問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 71問 · 2年前

    PROTEINS

    PROTEINS

    71問 • 2年前
    Yves Laure Pimentel

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    Yves Laure Pimentel · 7問 · 2年前

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    7問 • 2年前
    Yves Laure Pimentel

    ELECTROLYTES

    ELECTROLYTES

    Yves Laure Pimentel · 10問 · 2年前

    ELECTROLYTES

    ELECTROLYTES

    10問 • 2年前
    Yves Laure Pimentel

    DRUGS

    DRUGS

    Yves Laure Pimentel · 27問 · 2年前

    DRUGS

    DRUGS

    27問 • 2年前
    Yves Laure Pimentel

    TOXIC AGENTS:

    TOXIC AGENTS:

    Yves Laure Pimentel · 12問 · 2年前

    TOXIC AGENTS:

    TOXIC AGENTS:

    12問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    Yves Laure Pimentel · 100問 · 2年前

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    100問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    Yves Laure Pimentel · 29問 · 2年前

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    29問 • 2年前
    Yves Laure Pimentel

    hema diseases

    hema diseases

    Yves Laure Pimentel · 25問 · 2年前

    hema diseases

    hema diseases

    25問 • 2年前
    Yves Laure Pimentel

    AML

    AML

    Yves Laure Pimentel · 43問 · 2年前

    AML

    AML

    43問 • 2年前
    Yves Laure Pimentel

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    Yves Laure Pimentel · 71問 · 2年前

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    71問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    Yves Laure Pimentel · 31問 · 2年前

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    31問 • 2年前
    Yves Laure Pimentel

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    Yves Laure Pimentel · 34問 · 2年前

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    34問 • 2年前
    Yves Laure Pimentel

    PLATELET DISORDERS

    PLATELET DISORDERS

    Yves Laure Pimentel · 37問 · 2年前

    PLATELET DISORDERS

    PLATELET DISORDERS

    37問 • 2年前
    Yves Laure Pimentel

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    Yves Laure Pimentel · 100問 · 2年前

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    100問 • 2年前
    Yves Laure Pimentel

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    Yves Laure Pimentel · 12問 · 2年前

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    12問 • 2年前
    Yves Laure Pimentel

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    Yves Laure Pimentel · 39問 · 2年前

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    39問 • 2年前
    Yves Laure Pimentel

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    Yves Laure Pimentel · 55問 · 2年前

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    55問 • 2年前
    Yves Laure Pimentel

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    Yves Laure Pimentel · 37問 · 2年前

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    37問 • 2年前
    Yves Laure Pimentel

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    Yves Laure Pimentel · 44問 · 2年前

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    44問 • 2年前
    Yves Laure Pimentel

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    Yves Laure Pimentel · 50問 · 2年前

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    50問 • 2年前
    Yves Laure Pimentel

    1. HISTORY

    1. HISTORY

    Yves Laure Pimentel · 69問 · 2年前

    1. HISTORY

    1. HISTORY

    69問 • 2年前
    Yves Laure Pimentel

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    Yves Laure Pimentel · 38問 · 2年前

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    38問 • 2年前
    Yves Laure Pimentel

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    Yves Laure Pimentel · 21問 · 2年前

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    21問 • 2年前
    Yves Laure Pimentel

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    Yves Laure Pimentel · 15問 · 2年前

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    15問 • 2年前
    Yves Laure Pimentel

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    Yves Laure Pimentel · 32問 · 2年前

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    32問 • 2年前
    Yves Laure Pimentel

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    Yves Laure Pimentel · 30問 · 2年前

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    30問 • 2年前
    Yves Laure Pimentel

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    Yves Laure Pimentel · 38問 · 2年前

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    38問 • 2年前
    Yves Laure Pimentel

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    Yves Laure Pimentel · 48問 · 2年前

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    48問 • 2年前
    Yves Laure Pimentel

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    Yves Laure Pimentel · 35問 · 2年前

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    35問 • 2年前
    Yves Laure Pimentel

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 18問 · 2年前

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    18問 • 2年前
    Yves Laure Pimentel

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    Yves Laure Pimentel · 44問 · 2年前

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    44問 • 2年前
    Yves Laure Pimentel

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 23問 · 2年前

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    23問 • 2年前
    Yves Laure Pimentel

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    Yves Laure Pimentel · 34問 · 2年前

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    34問 • 2年前
    Yves Laure Pimentel

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    Yves Laure Pimentel · 12問 · 2年前

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    12問 • 2年前
    Yves Laure Pimentel

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    Yves Laure Pimentel · 16問 · 2年前

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    16問 • 2年前
    Yves Laure Pimentel

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    Yves Laure Pimentel · 15問 · 2年前

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    15問 • 2年前
    Yves Laure Pimentel

    12. ANTIBODY

    12. ANTIBODY

    Yves Laure Pimentel · 79問 · 2年前

    12. ANTIBODY

    12. ANTIBODY

    79問 • 2年前
    Yves Laure Pimentel

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    Yves Laure Pimentel · 97問 · 2年前

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    97問 • 2年前
    Yves Laure Pimentel

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    Yves Laure Pimentel · 11問 · 2年前

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    11問 • 2年前
    Yves Laure Pimentel

    1. INTERLEUKINS

    1. INTERLEUKINS

    Yves Laure Pimentel · 23問 · 2年前

    1. INTERLEUKINS

    1. INTERLEUKINS

    23問 • 2年前
    Yves Laure Pimentel

    2. INTERFERONS

    2. INTERFERONS

    Yves Laure Pimentel · 28問 · 2年前

    2. INTERFERONS

    2. INTERFERONS

    28問 • 2年前
    Yves Laure Pimentel

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    Yves Laure Pimentel · 8問 · 2年前

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    8問 • 2年前
    Yves Laure Pimentel

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 19問 · 2年前

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    19問 • 2年前
    Yves Laure Pimentel

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 76問 · 2年前

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    76問 • 2年前
    Yves Laure Pimentel

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    Yves Laure Pimentel · 21問 · 2年前

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    21問 • 2年前
    Yves Laure Pimentel

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    Yves Laure Pimentel · 29問 · 2年前

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    29問 • 2年前
    Yves Laure Pimentel

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    Yves Laure Pimentel · 19問 · 2年前

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    19問 • 2年前
    Yves Laure Pimentel

    19. CYTOKINES

    19. CYTOKINES

    Yves Laure Pimentel · 22問 · 2年前

    19. CYTOKINES

    19. CYTOKINES

    22問 • 2年前
    Yves Laure Pimentel

    20. INTERLEUKINS

    20. INTERLEUKINS

    Yves Laure Pimentel · 24問 · 2年前

    20. INTERLEUKINS

    20. INTERLEUKINS

    24問 • 2年前
    Yves Laure Pimentel

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    Yves Laure Pimentel · 21問 · 2年前

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21問 • 2年前
    Yves Laure Pimentel

    1. SERO

    1. SERO

    Yves Laure Pimentel · 54問 · 2年前

    1. SERO

    1. SERO

    54問 • 2年前
    Yves Laure Pimentel

    2. PRECIPITATION

    2. PRECIPITATION

    Yves Laure Pimentel · 38問 · 2年前

    2. PRECIPITATION

    2. PRECIPITATION

    38問 • 2年前
    Yves Laure Pimentel

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    Yves Laure Pimentel · 17問 · 2年前

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    17問 • 2年前
    Yves Laure Pimentel

    4. OUCHTERLONY

    4. OUCHTERLONY

    Yves Laure Pimentel · 15問 · 2年前

    4. OUCHTERLONY

    4. OUCHTERLONY

    15問 • 2年前
    Yves Laure Pimentel

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    Yves Laure Pimentel · 9問 · 2年前

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    9問 • 2年前
    Yves Laure Pimentel

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    Yves Laure Pimentel · 11問 · 2年前

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    11問 • 2年前
    Yves Laure Pimentel

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    Yves Laure Pimentel · 29問 · 2年前

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    29問 • 2年前
    Yves Laure Pimentel

    問題一覧

  • 1

    PHILIPPINE MEDICAL TECHNOLOGY ACT OF 1969 JUNE 21, 1969 32 SECTIONS

    RA 5527

  • 2

    RA 5527

    PHILIPPINE MEDICAL TECHNOLOGY ACT OF 1969 JUNE 21, 1969 32 SECTIONS

  • 3

    AMENDMENTS ON RA 5527

    RA 6138 , PD 498, PD 1534

  • 4

    Amends Sections 14 ,21, and 22

    RA 6138 (August 31, 1970)

  • 5

    PD 498 (June 28, 1974)

    Amends Sections 2,3,4,7,8,11,13,16,17,21 and 29

  • 6

    Amends Sections 2,3,4,7,8,11,13,16,17,21 and 29

    PD 498 (June 28, 1974)

  • 7

    PD 1534 (June 11, 1978)

    Amends Sections 3,8 and 13

  • 8

    Amends Sections 3,8 and 13

    PD 1534 (June 11, 1978)

  • 9

    TERM OF OFFICE BOARD OF MT HOLD OFFICE FOR ? AFTER APPOINTMENTS OR UNTIL THEIR SUCCESSORS SHALL HAVE BEEN APPOINTED AND DULY QUALIFIED

    THREE YEARS

  • 10

    BEFORE THE BOARD OR BEFORE ANY PERSON AUTHORIZED TO ADMINISTER PATHS PRIOR TO ENTERING UPON THE PRACTICE OF MT

    OATHTAKING

  • 11

    ISSUANCE OF COR ISSUED TO ANY SUCCESFUL APPLICANT WHO HAS ATTAINED?

    AGE OF 21 YEARS

  • 12

    ADMINISTRATIVE INVESTIGATION CONDUCTED BY ?

    ATLEAST TWO MEMBERS OF THE BOARD WITH ONE LEGAL OFFICER

  • 13

    UNANIMOUS VOTE OF ALL THREE MEMBERS OF THE BOARD

    REVOCATION

  • 14

    MAJORITY VOTE; NOT TO EXCEED 2 YEARS

    SUSPENSION

  • 15

    SUSPENSION MAJORITY VOTE; NOT TO

    EXCEED 2 YEARS

  • 16

    CLINICAL LABORATORY ACT JUNE 18, 1966

    RA 4688

  • 17

    RA 4688

    CLINICAL LABORATORY ACT JUNE 18, 1966

  • 18

    REVISED RULES AND REGULATIONS GOVERNING THE LICENSURE OF CLINICAL LABORATORIES IN THE PHILIPPINES AUGUST 22, 2007

    AO No 2007-0027

  • 19

    AO No 2007-0027 DATE

    AUGUST 22, 2007

  • 20

    PRIMARY CATEGORY LABORATORY

    ROUTINE HEMATOLOGY QUALITATIVE PLATELET DETERMINATION ROUTINE URINALYSIS ROUTINE FECALYSIS BLOOD TYPING - FOR HOSPITAL BASED

  • 21

    ROUTINE HEMATOLOGY QUALITATIVE PLATELET DETERMINATION ROUTINE URINALYSIS ROUTINE FECALYSIS BLOOD TYPING - FOR HOSPITAL BASED

    PRIMARY CATEGORY LABORATORY

  • 22

    SECONDARY CATEGORY LABORATORY

    SERVICES OF PRIMARY CATEGORY LABORATORY ROUTINE CC QUANTITATIVE PLATELET DETERMINATION CROSS-MATCHING- FOR HOSPITAL BASED GRAM STAINING- FOR HOSPITAL BASED KOH- FOR HOSPITAL BASED

  • 23

    SERVICES OF PRIMARY CATEGORY LABORATORY ROUTINE CC QUANTITATIVE PLATELET DETERMINATION CROSS-MATCHING- FOR HOSPITAL BASED GRAM STAINING- FOR HOSPITAL BASED KOH- FOR HOSPITAL BASED

    SECONDARY CATEGORY LABORATORY

  • 24

    VALIDITY OF LTO CLINICAL LABORATORY

    1 YEAR

  • 25

    NON HOSPITAL BASED CLINICAL LABORATORIES SHALL FILES APPILICATIONS FOR RENEWAL OF LTO ? OF THE CURRENT YEAR

    BEGINNING ON THE FIRST DAY OF OCTOBER UNTIL THE LAST DAY OF NOVEMBER

  • 26

    BLOOD BANKING LAW OF 1956 JUNE 16, 1956

    RA 1517

  • 27

    RA 1517

    BLOOD BANKING LAW OF 1956 JUNE 16, 1956

  • 28

    NATIONAL BLOOD SERVICES ACT OF 1994 MAY 5 1994

    RA 7719

  • 29

    RA 7719

    NATIONAL BLOOD SERVICES ACT OF 1994 MAY 5 1994

  • 30

    GUIDELINES ON THE IMPLEMENTATION OF RAPID HIV DIAGNOSTIC ALGORITHM JANUARY 10, 2019

    DOH A.O. NO. 2019-0001

  • 31

    DOH A.O. NO. 2019-0001 DATE

    JANUARY 10, 2019

  • 32

    All results of HIV/AIDS testing shall be confidential and shall be released only to the folowing persons The person who submitted himself/herself to such a test either parent of a minor child who has been tested a legal guardian in the case of insane persons or orphans a person authorized to recelve such results in conjunction with the AIDSWATCH program a justice of the Court of Appeals or the Supreme Court

    HIV RESULT : RA 8504

  • 33

    PHILIPPINE HIV AND AIDS POLICY ACT DECEMBER 20, 2018

    RA 11166

  • 34

    RA 11166

    PHILIPPINE HIV AND AIDS POLICY ACT DECEMBER 20, 2018

  • 35

    Results of any test related to HIV shall be disclosed by the trained service provider who conducts pre-test and post-test counseling to: *Individual who submitted to the test. *If the patient is below fifteen (15) years old, an orphan, or is mentally incapacitated, the result may de disclose to either of the patient's parents, legal guardian, or a duly assigned licensed social worker or health worker, whichever is applicable *A person below fifteen(15) years of age and not suffering from any mental incapacity, has given voluntary and informed consent to the procedure, the result of the test shall be disclose to child, provided that the child should be given age-appropriate counseling and access to necessary health care and sufficient support services. *Person authorized to receive such results in conjunction with the DOH *Monitoring Body.

    HIV RESULT: RA 11166

  • 36

    NEWBORN SCREENING ACT OF 2004 APRIL 7, 2004 DISORDERS SCREENED: - CONGENITAL HYPOTHYROIDISM - CONGENITAL ADRENAL HYPERPLASIA - GALACTOSEMIA - PHENYLKETONURIA - G6PD DEFICIENCY

    RA 9288

  • 37

    WHAT IS RA 9288 , DATE AND DISORDERS SCREENED

    NEWBORN SCREENING ACT OF 2004 APRIL 7, 2004 DISORDERS SCREENED: - CONGENITAL HYPOTHYROIDISM - CONGENITAL ADRENAL HYPERPLASIA - GALACTOSEMIA - PHENYLKETONURIA - G6PD DEFICIENCY

  • 38

    INCLUSION OF MSUP IN NEWBOR SCREENING. MSUD APPEARS TO BE THE MOST COMMON INBORN ERROR OF METABOLISM IN THE PHILIPPINES

    DOH MEMO 2012-0154

  • 39

    EXPANDED NEWBORN SCREENING INCREASE THE SCREENING PANEL OF DISORDERS FORM?

    6 TO 28

  • 40

    INCREASE THE SCREENING PANEL OF DISORDERS FORM 6 TO 28

    EXPANDED NEWBORN SCREENING

  • 41

    Dangerous DRUG ACT OF 1972

    RA 6425

  • 42

    RA 6425

    Dangerous DRUG ACT OF 1972

  • 43

    COMPRHENSIVE DANGEROUS DRUG ACT OF 2002

    RA 9165

  • 44

    RA 9165

    COMPRHENSIVE DANGEROUS DRUG ACT OF 2002

  • 45

    methylenedioxymethamphetamine

    ECSTASY

  • 46

    ECSTASY

    methylenedioxymethamphetamine

  • 47

    CANNABIS

    MARIJUANA OR INDIAN HEMP

  • 48

    MARIJUANA OR INDIAN HEMP

    CANNABIS

  • 49

    METHAMPETHAMINE HYDROCHLORIDE

    SHABU, ICE, OR METH

  • 50

    SHABU, ICE, OR METH

    METHAMPETHAMINE HYDROCHLORIDE

  • 51

    INDIVIDUAL FROM WHOM A SPECIMEN IS COLLECTED

    DONOR/CLIENT

  • 52

    DRUG TEST IS VALID FOR?

    1 YEAR

  • 53

    ACRREDITATION OF DRUG TESTING LABORATORY

    DOH

  • 54

    HEAD OF DRUG SCREENING LABORATORY IN CASES WHERE THE SCREENING DRUG TESTING LABORATORY IS A DIVISION, SECTION, OR UNIT OF CLINICAL LABORATORY, IT SHALL BE HEADED BY A LICENSED PHYSICIAN, CHEMIST, MEDICAL TECHNOLOGIST, PHARMACIST OR CHEMICAL ENGINEER.

    PATHOLOGIST

  • 55

    HEAD OF DRUG SCREENING LABORATORY IN CASES WHERE THE SCREENING DRUG TESTING LABORATORY IS A DIVISION, SECTION, OR UNIT OF CLINICAL LABORATORY, IT SHALL BE HEADED BY A LICENSED ?

    PHYSICIAN, CHEMIST, MEDICAL TECHNOLOGIST, PHARMACIST OR CHEMICAL ENGINEER.

  • 56

    HEAD OF DRUG CONFIRMATORY LABORATORY PATHOLOGIST WITH AT LEAST HOW MANY YEARS ACTIVE LABORATORY EXPERIENCE IN ANALYTICAL TOXICOLOGY

    2 YEARS

  • 57

    STUDENTS OF SECONDARY AND TERTIARY SCHOOLS OFFICERS AND EMPLOYEES OF PUBLIC AND PRIVATE OFFICES WHETHER DOMESTIC OR OVERSEAS

    RANDOM DRUG TEST

  • 58

    ACCREDITATION OF DRUG TESTING LAB VALID FOR A PERIOD OF:

    1 YEAR FOR SCREENING LABORATORY 2 YEARS FOR CONFIRMATORY LABORATORY

  • 59

    WHAT AO RULES AND REGULATIONS GOVERNING THE ACCREDITATION OF LABORATORIES FOR DRINKING WATER ANALYSIS 1. PHYSICAL ANALYSIS 2. CHEMICAL ANALYSIS 3. RADIOLOGICAL ANALYSIS 4. BACTERIOLOGIC ANALYSIS

    DOH A.O. No. 2006-0024

  • 60

    RULES AND REGULATIONS GOVERNING THE ACCREDITATION OF LABORATORIES FOR DRINKING WATER ANALYSIS (4)

    1. PHYSICAL ANALYSIS 2. CHEMICAL ANALYSIS 3. RADIOLOGICAL ANALYSIS 4. BACTERIOLOGIC ANALYSIS

  • 61

    ACCREDITATION OF LAB FOR DRINKING WATER ANALYSIS

    2 YEARS AND EXPIRES ON THE LAST DAY OF DECEMBER

  • 62

    CREATION OF PRC JUNE 22, 1973

    PD 223

  • 63

    PD 223

    CREATION OF PRC JUNE 22, 1973

  • 64

    PRC MODERNIZATION ACT OF 2000 DECEMBER 5, 2000 THREE MAN COMISSION - TEOFILO PILANDO -YOLANDA REYES - JOSE CUTEO, JR.

    RA 8981

  • 65

    RA 8981

    PRC MODERNIZATION ACT OF 2000 DECEMBER 5, 2000

  • 66

    THREE MAN COMISSION

    - TEOFILO PILANDO -YOLANDA REYES - JOSE CUTEO, JR.

  • 67

    CONTINUING PROFESSIONAL DEVELOPMENTAL ACT OF 2016

    RA 10912

  • 68

    RA 10912

    CONTINUING PROFESSIONAL DEVELOPMENTAL ACT OF 2016

  • 69

    45 CREDITS UNITS REQUIRED FOR MT EVERY 3 YEARS

    PRC Resolution No. 2016-990

  • 70

    PRC Resolution No. 2016-990 ? CREDITS UNITS REQUIRED FOR MT EVERY 3 YEARS

    45

  • 71

    PRC Resolution No. 2016-990 45 CREDITS UNITS REQUIRED FOR MT EVERY ?

    3 YEARS

  • 72

    CPD shall reduced the required CPD credit units to a minimum, which shall not be more than 15 units Professional working overseas shall NOT be covered by CPD requirement Newly Licensed professionals shall NOT be covered by the CPD requirement for the first renewal cycle.

    PRC Resolution No. 2019-1146

  • 73

    CPD shall reduced the required CPD credit units to a minimum, which shall not be more than ? units

    15

  • 74

    Contains your specific promises to: 1. Undertake to comply with the required number of CPD credit units during the validity of your PRC ID 2. Submit proof of compliance with the required number of CPD units during the next renewal of PRC ID.

    AFFIDAVIT OF UNDERTAKING

  • 75

    FAILURE TO GIVE REASONABLE CARE BY THE HEALTH-CARE PROVIDER

    NEGLIGENCE

  • 76

    MISCONDUCT OR LACK SKILL BY A HEALTH-CARE PROFESSIONAL THAT RESULTS IN INJURY TO THE PATIENT

    MEDICAL MALPRACTICE

  • 77

    Respecting the decisions made by those capable of making decisions. also includes respecting the _ of people whose ability to make decisions is limited.

    AUTONOMY

  • 78

    Doing good or providing benefit

    BENEFICIENCE

  • 79

    Avoid doing harm, or minimize harm as much as possible if it is unavoidable

    NON-MALEFICENCE

  • 80

    Ensuring fairness and equity in the distribution of risks and benefits. This includes the idea of treating equals equally and recognizing relevant inequalities

    JUSTICE

  • 81

    4 MANAGEMENT

    PLANNING ORGANIZING DIRECTING CONTROLLING

  • 82

    Identifying goals, evaluate current situation, establish time frame, set objectives, forecast resource need, implement plan, obtain feedback.

    PLANNING

  • 83

    Formal hierarchy, informal relationships

    ORGANIZING

  • 84

    Leadership, time allocation

    DIRECTING

  • 85

    Instructions, follow-up, modifications

    CONTROLLING

  • 86

    PROVIDES RECOMMENDATION FOR THE NUMBER OF STAFF (PHLEBOTOMISTS, CLERKS, TECHNICAL PERSONNEL, AND SO ON) NEEDED TO HANDLE AN UNPREDICTABLE WORKLOAD.

    QUEUING THEORY